New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
05:55 EDTAZN, WFMStocks with implied volatility below IV index mean; WFM AZN
Stocks with implied volatility below IV index mean; Whole Foods (WFM) 29, AstraZeneca (AZN) 22 according to iVolatility.
News For AZN;WFM From The Last 14 Days
Check below for free stories on AZN;WFM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
August 18, 2014
07:57 EDTAZNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 14, 2014
17:46 EDTWFMRelational Investors gives quarterly update on stakes
NEW STAKES: Whole Foods Market (WFM). INCREASED STAKES: Clean Harbors (CLH), Magnum Hunter Resources (MHR), Manitowoc (MTW), Esterline Technologies (ESL), and Yum! Brands (YUM). DECREASED STAKES: Bunge (BG), and Hologic (HOLX). LIQUIDATED STAKES: W.R. Grace & Co (GRA), and First American Financial (FAF).
12:01 EDTAZNThird Point gives quarterly update on stakes
NEW STAKES: Rackspace (RAX), Finisar (FNSR), Amgen (AMGN), Ally Financial (ALLY), and AstraZeneca (AZN). INCREASED STAKES: Dollar General (DG) and Dow Chemical (DOW). DECREASED STAKES: FedEx (FDX), Hertz (HTZ), T-Mobile (TMUS) and Intrexon (XON). LIQUIDATED STAKES: Google Class A (GOOGL), Verizon (VZ) and Mondelez (MDLZ).
August 13, 2014
08:31 EDTAZNAstraZeneca says Phase 3 trials of lesinurad for gout met primary endpoints
AstraZeneca announced top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor, as a combination therapy for the treatment of patients with symptomatic gout. Lesinurad is an investigational agent that inhibits the URAT1 transporter, increasing uric acid excretion and thereby lowering serum uric acid. In the CLEAR1 and CLEAR2 trials, both lesinurad 200mg and 400mg in combination with allopurinol met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0mg/dL at month 6 compared to allopurinol alone. In the CRYSTAL trial, lesinurad 400mg in combination with febuxostat met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <5.0mg/dL at month 6 compared to febuxostat alone. Although lesinurad 200mg did not achieve statistical significance at month 6, this dose in combination with febuxostat, was superior to placebo plus febuxostat at all other time points. Results from these Phase III clinical trials will be submitted to a scientific meeting later in 2014. The company is proceeding with preparation of regulatory submissions for lesinurad 200mg combination therapy.
August 12, 2014
10:06 EDTWFMWhole Foods Markets call activity attributed to takeover speculation
Whole Foods Markets August weekly 39 and 39.5 calls are active on total call volume of 12K contracts (2K puts) on takeover speculation. August call option implied volatility is at 36, September is at 28, November Is at 30, January is at 31; compared to its 26-week average of 33 according to Track Data. Active call volume suggests traders taking positions for larger near term price movement.
09:43 EDTWFMRumor: Whole Foods strength attributed to takeover speculation
05:58 EDTAZNStocks with implied volatility movement; P AZN
Subscribe for More Information
August 7, 2014
06:13 EDTAZNDynavax says AZD1419 Phase 1 study met secondary endpoints
Subscribe for More Information
August 6, 2014
10:59 EDTWFMOptions with decreasing implied volatility
Subscribe for More Information
09:19 EDTAZNShire, AstraZeneca, Smith & Nephew slump amid inversion fears, FT says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use